Post-surgical depressive symptoms and long-term survival in non-metastatic breast cancer patients at 11-year follow-up
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Background Mild to moderate depressive symptoms are common during treatment for non-metastatic breast cancer. The goal of this secondary analysis was to determine if depressive symptoms predict clinical outcomes at long-term follow-up. Methods From 1998-2005, we interviewed 231 women with the Hamilton Rating Scale for Depression who were participating in a psychosocial study 2-10 weeks post-surgery for nonmetastatic breast cancer (Stage 0-IIIb). We conducted Kaplan Meier (K-M) curves and Cox proportional hazards (PH) models to examine associations between depressive symptoms, overall survival, and disease-free survival at 8-15 year follow-up. Results A total of 95 women (41.1%) scored in the mild-moderately depressed range. Non-depressed women had longer overall survival (M=13.56 years; SE=.26) than those in the mild/moderate depressed group (M=11.45 years; SE=.40), Log-rank χ2(1)=4.41, p=.036. Cox PH models, adjusting for covariates, showed comparable results: mild/moderate depressive symptoms hazard ratio=2.56, [95% CI, 1.11 to 5.91], p=.027. Similar results were observed in a subsample with invasive disease (n=191). Depression category did not predict disease-free survival in the overall or invasive sample. Conclusions Screening and referrals for treatment of depressive symptoms, even at subclinical levels, is important early in treatment. A randomized trial is warranted to determine effects of depressive symptoms on clinical outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitchell, A. J., Chan, M., Bhatti, H., Halton, M., Grassi, L., Johansen, C., & Meader, N. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70002-x · Cited by 2,449 · cited 6×
“This study is novel in that we observed these associations in women who did not initially have MDD or major psychopathology.”
BackgroundInfluentialBabyak, M. A. (2004) · Psychosomatic Medicine · doi:10.1097/01.psy.0000127692.23278.a9 · Cited by 2,061
Severity classification on the Hamilton depression rating scale
Zimmerman, M., Martinez, J. H., Young, D., Chelminski, I., & Dalrymple, K. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.04.028 · Cited by 1,199 · cited 2×
“Findingswere robust whether depressive symptoms were tested on a severity continuum, as low versus mild/moderate depressive symptoms subgroups, or as no/ low versus mild versus moderate depressive symptom subgroups using accepted clinical cut-offs [17,18].”
BackgroundMethodDepression and cancer mortality: a meta-analysis
Pinquart, M., & Duberstein, P. R. (2010) · Psychological Medicine · doi:10.1017/s0033291709992285 · Cited by 1,083 · cited 5×
“Findings are in line with meta-analyses showing that higher levels of depressive symptoms predict elevated mortality in cancer patients [6,7] and in breast cancer patients specifically [4].”
BackgroundResultInfluentialDiurnal Cortisol Rhythm as a Predictor of Breast Cancer Survival
Sephton, S. E. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.12.994 · Cited by 1,082
Do stress-related psychosocial factors contribute to cancer incidence and survival?
Chida, Y., Hamer, M., Wardle, J., & Steptoe, A. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1134 · Cited by 1,072 · cited 2×
“Findings are in line with meta-analyses showing that higher levels of depressive symptoms predict elevated mortality in cancer patients [6,7] and in breast cancer patients specifically [4].”
BackgroundResultDepression as a predictor of disease progression and mortality in cancer patients: A Meta‐Analysis
Satin, J. R., Linden, W., & Phillips, M. J. (2009) · Cancer · doi:10.1002/cncr.24561 · Cited by 972
Depression and cancer: mechanisms and disease progression
Spiegel, D., & Giese-Davis, J. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00566-3 · Cited by 874 · cited 3×
“Other studies show no relationship between depressive symptoms and survival among breast cancer patients [13,14].”
BackgroundAndersen, B. L., DeRubeis, R. J., Berman, B. S., Gruman, J., Champion, V. L., Massie, M. J., Holland, J. C., Partridge, A. H., Bak, K., Somerfield, M. R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.4611 · Cited by 735 · cited 1×
“Psychiatric symptoms increase risk for disease-related morbidity and mortality [34]; however, the psychological needs of these patients are largely unmet.”
BackgroundGiese-Davis, J., Collie, K., Rancourt, K. M. S., Neri, E., Kraemer, H. C., & Spiegel, D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.4455 · Cited by 458
Cognitive-Behavioral Stress Management Reverses Anxiety-Related Leukocyte Transcriptional Dynamics
Antoni, M. H., Lutgendorf, S. K., Blomberg, B., Carver, C. S., Lechner, S., Diaz, A., Stagl, J., Arevalo, J. M. G., & Cole, S. W. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.10.007 · Cited by 251 · cited 1×
“Alleviating depressive symptoms during primary treatment may help normalize neuroendocrine and inflammatory processes [31], which could provide health benefits.”
BackgroundSelf-citationDepression as a Prognostic Factor for Breast Cancer Mortality
Hjerl, K., Andersen, E. W., Keiding, N., Mouridsen, H. T., Mortensen, P. B., & Jørgensen, T. (2003) · Psychosomatics · doi:10.1176/appi.psy.44.1.24 · Cited by 223 · cited 1×
“Results are consistent with studies showing that depressive symptoms predict mortality in breast cancer, as demonstrated in samples of non-metastatic [10,11] and metastatic breast cancer [9], and in a study combining all breast cancer stages [12].”
ResultCohen, L., Cole, S. W., Sood, A. K., Prinsloo, S., Kirschbaum, C., Arevalo, J. M. G., Jennings, N. B., Scott, S., Vence, L., Wei, Q., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042324 · Cited by 197
Depression, cortisol, and suppressed cell-mediated immunity in metastatic breast cancer
Sephton, S. E., Dhabhar, F. S., Keuroghlian, A. S., Giese-Davis, J., McEwen, B. S., Ionan, A. C., & Spiegel, D. (2009) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2009.07.007 · Cited by 170 · cited 1×
“Cortisol dysregulation, frequently observed in depressed patients [29], predicts shorter overall survival in breast cancer [26], and is a potential mediating pathway [14], In breast cancer patients, inflammatory cytokines are associated with degree of depressive symptoms [30], and evidence”
Background
Cited by
The impact of psychosocial stress and stress management on immune responses in patients with cancer
Antoni, M. H., & Dhabhar, F. S. (2019) · Cancer · doi:10.1002/cncr.31943 · Cited by 394
Self-citationXie, W., Gao, Q., Guo, Z., Wang, D., Gao, F., Wang, X., Wei, Y., & Zhao, L. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b10699 · Cited by 206
Antoni, M. H., Moreno, P. I., & Penedo, F. J. (2023) · Annual Review of Psychology · doi:10.1146/annurev-psych-030122-124119 · Cited by 132
“For instance, greater depressive symptoms predict shorter overall survival in patients treated for nonmetastatic (Antoni et al. 2017) and metastatic (Giese-Davis et al. 2011) breast cancer and in patients with RCC (Cohen et al. 2012).”
BackgroundSelf-citationMajor Depression and Survival in People With Cancer
Walker, J., Mulick, A., Magill, N., Symeonides, S., Gourley, C., Burke, K., Belot, A., Quartagno, M., van Niekerk, M., Toynbee, M., et al. (2021) · Psychosomatic Medicine · doi:10.1097/psy.0000000000000942 · Cited by 124
Reis, J. C., Antoni, M. H., & Travado, L. (2020) · CNS Spectrums · doi:10.1017/s1092852918001621 · Cited by 44
Self-citation
Metadata
- Authors
- Antoni, M. H., Jacobs, J. M., Bouchard, L. C., Lechner, S. C., Jutagir, D. R., Gudenkauf, L. M., Blomberg, B. B., Glück, S., & Carver, C. S.
- Venue
- General Hospital Psychiatry
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 44
- Pages
- 16-21
- ISSN
- 0163-8343 (ISSN-L)
- OpenAlex
- W2538048502
- Cited by
- 46
- References
- 14
- FWCI
- 2.16
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.